Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: A population-based case control study

Journal of Ethnopharmacology

Volumn 156, Issue , 2014, Pages 358-364

  Hsu, Pei Chien ^a,b,c   Tsai, Yueh Ting ^a   Lai, Jung Nien ^a,b   Wu, Chien Tung ^a   Lin, Shun Ku ^a,b   Huang, Chung Yu ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chinese herbal product; Diabetes; Kidney failure; Liu Wei Di Huang Wan; National Health Insurance Research Database; Traditional Chinese medicine

Indexed keywords

HERBACEOUS AGENT; LIU WEI DI HUANG WAN; UNCLASSIFIED DRUG; LIU-WEI-DI-HUANG WAN;

ADULT; AGED; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; FEMALE; HEALTH CARE; HEALTH SERVICE; HUMAN; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; RISK REDUCTION; ADVERSE EFFECTS; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RISK; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; RENAL INSUFFICIENCY; RISK; YOUNG ADULT;

EID: 84909647448     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2014.08.029     Document Type: Article

References (36)

1. Adler, A.I., Stevens, R.J., Manley, S.E., Bilous, R.W., Cull, C.A., Holman, R.R., UKPDS Group, 2003. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 63, 225-232.
2. Ahmad, O.B., Boschi-Pinto, C., Lopez, A.D., Murray, C., Lozano, R., Inoue, M.. 2014. Age Standardization of Rates: A New WHO Standard, 2000. 〈http://www.who.int/healthinfo/paper31.pdf〉 (Accessed 20.02.14.).
3. Caro, J.J., Ward, A.J., O'Brien, J.A., 2002. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 25, 476-481.
4. Centers for Disease Control and Prevention. 2014. International classification of diseases, Ninth revision. 〈http://www.cdc.gov/nchs/icd/icd9.htm〉 (Accessed 20.03.14.).
5. Chuang, L.M., Tsai, S.T., Huang, B.Y., Tai, T.Y., 2001. The current state of diabetes management in Taiwan. Diabetes Research and Clinical Practice 54, S55-S65.
6. Cotton, C.A., Cuerden, M.S., Cook, R.J., 2011. Causal inference in nonrandomized studies via propensity score methods. Transfusion 51, 2536-2539.
7. Covington, M.B., 2001. Traditional Chinese medicine in the treatment of diabetes. Diabetes Spectrum 14, 154-159.
8. Department of Chinese Medicine and Pharmacy, Ministry of Health and Welfare, Executive Yuan, Taiwan. 2014a. Inquiry system of licenses of Chinese herbal products. 〈http://www.mohw.gov.tw/CHT/DOCMAP/query-liense.aspx?mode=1t〉 (Accessed 20.03.14.).
9. Department of Chinese Medicine and Pharmacy, Ministry of Health and Welfare, Executive Yuan, Taiwan. 2014b. Unified formulas. 〈http://www.mohw.gov.tw/CHT/DOCMAP/DM1.aspx?f-list-no=758&fod-list-no=3918〉 (Accessed 3.03.14.).
10. Harris, M.I., Eastman, R.C., 2000. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes/Metabolism Research and Reviews 16, 230-236.
11. Hsieh, S.C., Lai, J.N., Lee, C.F., Hu, F.C., Tseng, W.L., Wang, J.D., 2008. The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiology and Drug Safety 17, 609-619.
12. Huang, C.Y., Tsai, Y.T., Lai, J.N., Hsu, F.L., 2013. Prescription pattern of Chinese herbal products for diabetes mellitus in Taiwan: a population-based study. Evidence-Based Complementary and Alternative Medicine 2013, 201329.
13. Jiang, H.L., Niu, J.J., Zhang, W.F., Huang, W.J., Zhou, M.Y., Sha, W.J., Li, J.Y., Li, F.F., Zhu, T., Xia, X., Zhang, J., Shen, Y.D., Zhou, L.G., 2014. The role of central nervous system on hypoglycemia and the feasibility of the brain theory in traditional Chinese medicine on treatment of diabetes mellitus. Journal of Integrative Medicine 12, 1-6.
14. Jiang, Y.D., Chang, C.H., Tai, T.Y., Chen, J.F., Chuang, L.M., 2012. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. Journal of the Formosan Medical Association 111, 599-604.
15. Jungers, P., Chauveau, P., Descamps-Latscha, B., Labrunie, M., Giraud, E., Man, N.K., Grünfeld, J.P., Jacobs, C., 1996. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. Nephrology, Dialysis, Transplantation 11, 1542-1546.
16. Laakso, M., 1999. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48, 937-942.
17. Lai, M.N., Lai, J.N., Chen, P.C., Tseng, W.L., Chen, Y.Y., Hwang, J.S., Wang, J.D., 2009. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology 14, 227-234.
18. Lai, M.N., Lai, J.N., Chen, P.C., Hsieh, S.C., Hu, F.C., Wang, J.D., 2010. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. American Journal of Kidney Diseases 55, 507-518.
19. Li, H., Zhao, L., Zhang, B., Jiang, Y., Wang, X., Guo, Y., Liu, H., Li, S., Tong, X., 2014. A network pharmacology approach to determine active compounds and action mechanisms of Ge-Gen-Qin-Lian decoction for treatment of type 2 diabetes. Evidence-Based Complementary and Alternative Medicine 2014, 495840.
20. Martena, M.J., van der Wielen, J.C.A., van der Laak, L.F.J., Konings, E.J.M., de Groot, H.N., Rietjens, I.M.C.M., 2007. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Analytical and Bioanalytical Chemistry 389, 263-275.
21. Mazer, M., Perrone, J., 2008. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. Journal of Medical Toxicology: official journal of the American College of Medical Toxicology 4, 2-6.
22. Murray, M.D., Brater, D.C., 1993. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annual Review of Pharmacology and Toxicology 33, 435-465.
23. National Health Research Institutes in Taiwan. 2014. National Health Insurance Research Database. 〈http://nhird.nhri.org.tw/index.php〉 (Accessed 2.0314.).
24. National Kidney Foundation, 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 39, S1-266.
25. Peng, A., Gu, Y., Lin, S., 2005. Herbal treatment for renal diseases. Annals of the Academy of Medicine, Singapore 34, 44-51.
26. Perneger, T.V., Brancati, F.L., Whelton, P.K., Klag, M.J., 1994a. End-stage renal disease attributable to diabetes mellitus. Annals of Internal Medicine 121, 912-918.
27. Perneger, T.V., Whelton, P.K., Klag, M.J., 1994b. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. The New England Journal of Medicine 331, 1675-1679.
28. Poon, T.Y., Ong, K.L., Cheung, B.M., 2011. Review of the effects of the traditional Chinese medicine Rehmannia six formula on diabetes mellitus and its complications. Journal of diabetes 3, 184-200.
29. UK Prospective Diabetes Study 6, 1990. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Research 13, 1-11.
30. United States Renal Data Systems (USRDS). 2014a. Annual data report on ESRD, 2013. 〈http://www.usrds.org/atlas.aspx〉 (Accessed 19.0214.).
31. United States Renal Data Systems (USRDS). 2014b. Age-adjusted incidence of end-stage renal disease related to diabetes mellitus (ESRD-DM) per 100,000 diabetic population, by race, ethnicity, and sex, United States, 1980-2008. 〈http://www.cdc.gov/diabetes/statistics/esrd/fig5.htm〉 (Accessed 19.02.14.).
32. Vanhaelen, M., Vanhaelen-Fastre, R., But, P., Vanherweghem, J.L., 1994. Identification of aristolochic acid in Chinese herbs. Lancet 343, 174.
33. Wild, S., Roglic, G., Green, A., Sicree, R., King, H., 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053.
34. Zhang, P., Zhang, X., Brown, J., Vistisen, D., Sicree, R., Shaw, J., Nichols, G., 2010. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87, 293-301.
35. Zhang, X.J., Deng, Y.X., Shi, Q.Z., He, M.Y., Chen, B., Qiu, X.M., 2014. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism. Phytomedicine 21, 615-623.
36. Zhong, Y., Deng, Y., Chen, Y., Chuang, Y., He, C., 2013. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney International 84, 1108-1118.